- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01678417
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
September 4, 2012 updated by: Korea Cancer Center Hospital
A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Follicular lymphoma (FL) and mantle cell lymphoma (MCL) are rare lymphomas which consist of less than 5% of non-Hodgkin lymphoma in Korea.
Although FL with histologic grade 1 or 2 has relatively good prognosis, continual treatment is needed due to frequent relapse.
FL with histologic grade 3 has poor prognosis similar to that of diffuse large B cell lymphoma.
Meanwhile, the response rate to systemic chemotherapy in MCL is low, so the treatment of relapsed MCL is challenging.
So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with FL or MCL
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
29
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hye Jin Kang, M.D.
- Phone Number: +82-2-970-1289
- Email: mdhyejin@gmail.com
Study Contact Backup
- Name: Dong-Yeop Shin, M.D.
- Phone Number: +82-2-970-1246
- Email: baramg@hanmail.net
Study Locations
-
-
-
Seoul, Korea, Republic of, 139-706
- Recruiting
- Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences
-
Contact:
- Hye Jin Kang, M.D.
-
Contact:
- Dong-Yeop Shin, M.D.
-
Sub-Investigator:
- Sung Hyun Yang, M.D.
-
Sub-Investigator:
- Im Il Na, M.D.
-
Sub-Investigator:
- Hyo-Rak Lee, M.D.
-
Sub-Investigator:
- Dong-Yeop Shin, M.D.
-
Sub-Investigator:
- Sang Moo Lim, M.D.
-
Sub-Investigator:
- Byung Il Kim, M.D.
-
Sub-Investigator:
- Ilhan Lim, M.D.
-
Sub-Investigator:
- Seung-Sook Lee, M.D.
-
Sub-Investigator:
- Chang Woon Choi, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed follicular lymphoma or mantle cell lymphoma
- relapsed or refractory patients
- Eastern Cooperative Oncology Group performance status ≤ 2
- age≥ 20 years
- More than one measurable lesion (More than 2cm sized lesion in conventional CT scan,More than 1cm sized lesion in spiral CT or contrast-enhanced PET/CT)
- Adequate renal function (serum creatinine ≤ 2.0 mg/dl or Ccr ≥ 60 ml/min)
- Adequate hepatic function (serum bilirubin ≤ 2.0 mg/dl , AST/ALT ≤ 3 upper normal limit)
- Adequate bone marrow reservoir (ANC ≥1,500/㎕, platelet count≥ 75,000/㎕)
- patient who agree the purpose and intention of this clinical trial
Exclusion Criteria:
- recent (<5 years) history of other malignancy or unrecovered from the disease (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded)
- hemodynamically unstable due to the recent (<12 months) history of severe
- heart disease such as myocardial infarction
- acute complications of severe lung or metabolic disease
- Combined severe neurological or psychiatric disease
- Unrecovered from infection or other medical disease
- Recent (<30 days) history of enrollment of other clinical trial
- Pregnant or breast-feeding woman
- women of childbearing potential and men not employing adequate contraception at least for 1 year
- previous history drug allergy to the content of 131I-rituximab
- Infection(sepsis, pneumonia, viral infection, etc) (inactivated hepatitis B carrier can be enrolled)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 131I-rituximab
131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response rate
Time Frame: up to 5 years
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: up to 5 years
|
up to 5 years
|
Response duration
Time Frame: up to 5 years
|
up to 5 years
|
Number of Adverse Events
Time Frame: up to 5 years
|
up to 5 years
|
progression free survival
Time Frame: up to 5 years
|
up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hye Jin Kang, M.D., Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Anticipated)
June 1, 2017
Study Completion (Anticipated)
June 1, 2017
Study Registration Dates
First Submitted
August 30, 2012
First Submitted That Met QC Criteria
September 4, 2012
First Posted (Estimate)
September 5, 2012
Study Record Updates
Last Update Posted (Estimate)
September 5, 2012
Last Update Submitted That Met QC Criteria
September 4, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Mantle-Cell
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- FL or MCL 131I-rituximab RIT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
-
Hoffmann-La RocheCompletedRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell LymphomaUnited States, Spain, United Kingdom
-
AstraZenecaActive, not recruitingPhase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaChina
-
Janssen Biotech, Inc.Pharmacyclics LLC.Approved for marketingRelapsed or Refractory Mantle Cell LymphomaUnited States, Brazil, Puerto Rico
-
US Oncology ResearchEli Lilly and CompanyCompletedRelapsed or Refractory Mantle Cell Lymphoma (MCL)
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedIbrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma | Refractory Follicular...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditionsUnited States
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
MingSight Pharmaceuticals, IncShenzhen MingSight Relin Pharmaceutical Co., LtdRecruitingChronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)China
-
Allogene TherapeuticsActive, not recruitingRelapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Large B Cell LymphomaUnited States
Clinical Trials on 131I-rituximab
-
Korea Cancer Center HospitalUnknownRelapsed or Refractory Diffuse Large B Cell LymphomaKorea, Republic of
-
Korea Cancer Center HospitalUnknownRelapsed or Refractory Marginal Zone B-cell LymphomaKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterY-mAbs TherapeuticsAvailableCentral Nervous System/Leptomeningeal NeoplasmsUnited States
-
TransMolecularCompletedGlioma | Brain NeoplasmUnited States
-
Centre Jean PerrinRecruiting
-
Yale UniversityWithdrawn
-
Boehringer IngelheimTerminatedCarcinoma, Non-Small-Cell Lung
-
TransMolecularUnknownAstrocytoma | Glioblastoma Multiforme | Malignant Glioma | GBM | OligodendrogliomaUnited States
-
Y-mAbs TherapeuticsTerminatedNeuroblastoma | Leptomeningeal Metastases | CNS MetastasesUnited States, Denmark, Japan, Spain